Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.36 and traded as low as $0.28. Avenue Therapeutics shares last traded at $0.3053, with a volume of 1,129 shares.
Avenue Therapeutics Stock Performance
The stock has a 50 day moving average of $0.46 and a two-hundred day moving average of $0.35. The stock has a market cap of $1.01 million, a PE ratio of 0.02 and a beta of -0.32.
About Avenue Therapeutics
Avenue Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company has concentrated primarily on hospital-based treatments, with the goal of addressing pain management needs while offering alternatives to conventional opioid therapies. Avenue’s lead product candidate is intravenous (IV) tramadol, an investigational formulation of tramadol hydrochloride intended for the management of acute postoperative pain in adults who require an intravenous analgesic.
Recommended Stories
- Five stocks we like better than Avenue Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
